Alkermes rises after narcolepsy drug meets main goal in mid-stage trial

Alkermes

12/11/2025 12:51

** Shares of drug developer Alkermes ALKS.O rise 7.4% to $36.31 premarket

** Company says its experimental drug, alixorexton, met main goal in a mid-stage study in patients with narcolepsy type 2

** This condition is a rare, chronic neurological sleep disorder that affects the brain's ability to regulate the sleep-wake cycle

** Alkermes says alixorexton improved patients’ ability to stay awake after eight weeks of treatment, compared to placebo

** ALKS plans to initiate late-stage study for the drug in Q1 2026

** As of last close, stock up 17.6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))